作为项目负责人曾主持国家自然科学基金2项、北京市自然科学基金面上项目2项、中国博士后基金1项，北京市医院管理中心科研培育课题1项，北京市科协金桥工程种子资金2项。现主持中国高校产学研创新基金、北京市自然科学基金-昌平创新联合基金、北京市卫健委首都医学科技创新成果转化优促计划赋能项目、国家卫生健康委医院管理研究所医院药学高质量发展重点项目、北京市呼吸疾病研究所院所融合发展项目、北京市朝阳区数字医疗概念验证计划项目等科研项目。

入选北京市卫健委高层次公共卫生技术人才建设项目、北京市朝阳区2025年“凤凰计划”领军人才、北京市医管中心青苗人才培养项目、中国药学会医院药学专委会医院药学优秀人才项目、中国药学会施维雅青年医院药学奖、北京朝阳医院1351人才培养项目。

近五年作为第一作者/共同一作或独立通讯作者发表 SCI 论文75篇，合计影响因子 337.492，单篇最高影响因子12.70。

申报专利19项（第一发明人申报9项），其中作为第一发明人已获得专利授权5项。

1. Yang H, Wang Z, Jiang C, ZhangY, Zhang Y, Xu M, Zhang Y, Wang Y, Liu X,An Z*, Tong Z*. Oral azvudinefor mild-to-moderate COVID-19 in high risk,nonhospitalized adults: Results ofa real-world study. J Med Virol. 2023Jul;95(7):e28947. doi: 10.1002/jmv.28947.  （IF:12.7）   

2. Yang H*, Wang Z*, Zhang Y, XuM, Wang Y, Zhang Y, Liu X, An Z*, Tong Z*.Clinical characteristics andfactors for serious outcomes among outpatientsinfected with the Omicronsubvariant BF.7. J Med Virol. 2023 Aug;95(8):e28977.doi: 10.1002/jmv.28977.        （IF:12.7）   

3. HuT, Zhang W, Ding X, Han F, An Z. Plasma metabolomics disentangles T2DM- andCAD-specific dysmetabolism and identifies potential biomarkers for CAD riskescalation in diabetic patients. Cardiovasc Diabetol. 2025 Nov 19;24(1):440.doi: 10.1186/s12933-025-02981-5. （IF:10.6）

4. WangX, Ye Z, Busse JW, HillMD, Smith EE*, Guyatt GH, Prasad K, Lindsay MP, Yang H,Zhang Y, Liu Y, Tang B,Wang X, Wang Y, Couban RJ, An Z*. Endovascularthrombectomy with orwithout intravenous alteplase for acute ischemic stroke dueto large vesselocclusion: a systematic review and meta-analysis of randomizedtrials. StrokeVasc Neurol. 2022 Jun 20:svn-2022-001547. doi:10.1136/svn-2022-001547.     （IF:9.893） 

5. Xuan L, Ren L, Zhang W, Du P,Li B, AnZ*. Formaldehyde aggravates airway inflammation throughinduction of glycolysisin an experimental model of asthma exacerbated bylipopolysaccharide. Sci TotalEnviron. 2024 Feb 20;912:168947. doi:10.1016/j.scitotenv.2023.168947.    （IF:9.8）     

6. XianDing, Hongchuan Liu, Qingrong Qiu, Kongcai Zhu, Xiaohong Zhu, Rui Zhao, TingHu, Yuan Sun, Zhuoling An. Metabolic heterogeneity, networks, and biomarkers ofdrug-induced liver injury,Journal of Pharmaceutical Analysis,2025,101496. (IF:8.9)

7. ZhaoR#, An Z#, Sun Y,Xia L, Qiu L, Yao A, Liu Y*, Liu L*. Metabolic profiling inearly pregnancy andassociated factors of folate supplementation: Across-sectional study. ClinNutr. 2021 Sep;40(9):5053-5061. doi:10.1016/j.clnu.2021.01.012.      （IF:7.324） 

8. Ma Z#, Sun X#, Zhang Y, Li H,Sun D, An Z*, Zhang Y*. Risk ofThromboembolic Events in Cancer PatientsTreated with Immune CheckpointInhibitors: A Meta-analysis of RandomizedControlled Trials. Thromb Haemost.2022 Jun 30. doi: 10.1055/s-0042-1749185.     （IF:6.681） 

9. Ye Z, Busse JW, Hill MD,Lindsay MP, Guyatt GH, Prasad K, Agarwal A,Beattie C, Beattie J, Dodd C, HeranMKS, Narayan S, Chartúir NN, O'Donnell M, Resmini I,Sacco S, Sylaja PN, Volders D, Wang X,Xie F, Zachrison KS, Zhang L, Zhong H, AnZ*, Smith EE. Endovascularthrombectomy and intravenous alteplase inpatients with acute ischemic strokedue to large vessel occlusion: A clinicalpractice guideline. J Evid Based Med.2022 Sep;15(3):263-271. doi:10.1111/jebm.12493.        （IF:6.224） 

10. Du P*, Wang G, Hu T, Li H, AnZ*. Integration Analysis ofPharmacokinetics and Metabolomics to PredictMetabolic Phenotype and DrugExposure of Remdesivir. Front Pharmacol. 2022 Jan5;12:779135. doi:10.3389/fphar.2021.779135.    （IF:5.988）

11.  An Z#, Zhao R#, Han F, Sun Y, Liu Y*, Liu L*. Potential SerumBiomarkersAssociated with Premature Rupture of Fetal Membranes in the FirstTrimester.Front Pharmacol. 2022 Jul 8;13:915935. doi: 10.3389/fphar.2022.915935.     （IF:5.988）

12. Hu T*, Sun Y, An Z*.Dose- andtime-dependent manners of moxifloxacin induced liver injury bytargetedmetabolomics study. Front Pharmacol. 2022 Sep 16;13:994821.doi:10.3389/fphar.2022.994821.    （IF:5.988） 

13. Wang X, Turhon M, Yang X, LiuJ, ZhangH, Li T, Song D, Zhao Y, Guan S, Maimaitili A, Wang Y, Feng W, Wan J,Mao G, ShiH, An Z*, Wang Y*. Could statin improve outcomes afterpipeline embolization forintracranial aneurysms in a real-world setting? TherAdv Neurol Disord. 2023 May10;16: 17562864231170517. doi:10.1177/17562864231170517.       （IF:5.9）     

14. Hu T*, Zhang W, Han F, Zhao R,Liu L, AnZ*. Plasma fingerprint of free fatty acids and theircorrelations with thetraditional cardiac biomarkers in patients with type 2diabetes complicated bycoronary heart disease. Front Cardiovasc Med. 2022 Jul22;9:903412. doi:10.3389/fcvm.2022.903412.     （IF:5.846） 

15. Ren L#, Xuan L#, Li A#, Yang Y,Zhang W,Zhang J, Zhang Y, An Z*. Gamma-aminobutyric acidsupplementation improvesolanzapine-induced insulin resistance by inhibitingmacrophage infiltration inmice subcutaneous adipose tissue. Diabetes ObesMetab. 2024 Jul;26(7):2695-2705.doi: 10.1111/dom.15585.    （IF:5.8）     

16. Yang H, Yu X, An Z*.Cutaneous ToxicityAssociated With Enfortumab Vedotin: A Real-Word StudyLeveraging U.S. Food andDrug Administration Adverse Event Reporting System.Front Oncol. 2022 Jan19;11:801199. doi: 10.3389/fonc.2021.801199.  （IF:5.738）

17. Hu Y#, Lu W#, Tang B, Zhao Z*, AnZ*.Urinary incontinence as a possible signal of neuromuscular toxicityduringimmune checkpoint inhibitor treatment: Case report andretrospectivepharmacovigilance study. Front Oncol. 2022 Sep 12;12:954468.doi:10.3389/fonc.2022.954468.      （IF:5.738）

18. Hang Y, Ran L, Liang Y, ZhangY, An Z*.Safety analysis of pemigatinib leveraging the US Food and Drugadministrationadverse event reporting system. Front Pharmacol. 2023 Jul24;14:1194545. doi:10.3389/fphar.2023.1194545.      （IF:5.6）     

19. Yang H, Wang Z, Zhang Y, Xu M,Wang Y,Zhang Y, An Z*, Tong Z*. Effectiveness of inactivated COVID-19vaccines againstSARS-CoV-2 Omicron subvariant BF.7 among outpatients inBeijing, China. Vaccine.2023 Nov 22;41(48):7201-7205. doi:10.1016/j.vaccine.2023.10.036.   （IF:5.5）     

20. Du P*, Xuan L, An Z*,Zhang Y*.Development and validation of a robust and sensitive HPLC-MS/MSmethod for thequantitation of MRTX849 in plasma and its application inpharmacokinetics.Analyst. 2022 Mar 14;147(6):1175-1180. doi:10.1039/d1an01928g.        （IF:5.227) 

21. Cong L†,Wan Z†, Li P†, Liu D, He J*, AnZ*, Liu L.Metabolic, genetic, and pharmacokinetic parameters for theprediction ofolanzapine efficacy. Eur J Pharm Sci. 2022 Aug 15:106277.doi:10.1016/j.ejps.2022.106277.    (IF:5.112)

22. Ting Hu, Yu Tang, Feifei Han, XianDing, Zhuoling An.Development and validation of a machine learning-basedretention time prediction model for glycosphingolipids in UHPLC-HRMS analysis,Microchemical Journal,Volume 218,2025,115318.

23. Hu T, Zhang W, Han F, Zhao R,Liu H, AnZ*. Machine learning reveals serum myristic acid, palmiticacid andheptanoylcarnitine as biomarkers of coronary artery disease risk inpatientswith type 2 diabetes mellitus. Clin Chim Acta. 2024 Mar 15;556:117852.doi:10.1016/j.cca.2024.117852.     (IF:5) 

24. Yang H, Yu X, Hou W, Liu X,Chen J,Zhang Y, Wang Y, Zhu Y, Qian Q, Ma K, An Z*. Effectiveness andsafety ofnirmatrelvir-ritonavir in kidney transplant recipients with severekidneydysfunction infected with COVID-19. Antimicrob Agents Chemother. 2024Mar6;68(3):e0138423. doi: 10.1128/aac.01384-23.   （IF:4.9）     

25. Hu T#, An Z#, Sun Y,Wang X, Du P, Li P,Chi Y*, Liu L*. Longitudinal Pharmacometabonomics forPredicting Malignant TumorPatient Responses to Anlotinib Therapy: Phenotype,Efficacy, and Toxicity. FrontOncol. 2020 Nov 12;10:548300. doi:10.3389/fonc.2020.548300.      （IF:4.848） 

26. Hu T, Sun Y, Li H, Du P, LiuL*, An Z*.Dual derivatization strategy for the comprehensivequantification and doublebond location characterization of fatty acids byultra-high performance liquidchromatography-tandem mass spectrometry. JChromatogr A. 2021 Feb22;1639:461939. doi: 10.1016/j.chroma.2021.461939.       （IF:4.759）

27. Wang X#, Wang C#, Zhang Y*, AnZ*.Effect of pharmacogenomics testing guiding on clinical outcomes inmajordepressive disorder: a systematic review and meta-analysis of RCT.BMCPsychiatry. 2023 May 12;23(1):334. doi: 10.1186/s12888-023-04756-2.        （IF:4.4）

28. Sun X#, Wang H#, Zhan X, Yan Y,Chen K,An Z*, Zhou H*. Comparison of the safety profiles forpirfenidone andnintedanib: a disproportionality analysis of the US food anddrug administrationadverse event reporting system. Front Pharmacol. 2024 May27;15:1256649. doi:10.3389/fphar.2024.1256649.      （IF:4.4）     

29. Ting Hu, Yu Tang, Feifei Han, XianDing, Zhuoling An.Development and validation of a machine learning-basedretention time prediction model for glycosphingolipids in UHPLC-HRMS analysis,Microchemical Journal,Volume 218,2025,115318.(IF:4.4)

30. Hu T#*, Li H#, Xu B, Du P, LiuL, An Z*.Parallel derivatization strategy for comprehensive profilingof unconjugated andglycine-conjugated bile acids using Ultra-high performanceliquidchromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol.2021Nov;214:105986. doi: 10.1016/j.jsbmb.2021.105986.        （IF:4.292）

31. Zhang Y#, Ma Z#, Sun X, FengX*, An Z*.Interstitial lung disease in patients treated withCyclin-Dependent Kinase 4/6inhibitors: A systematic review and meta-analysisof randomized controlledtrials. Breast. 2022 Apr;62:162-169. doi:10.1016/j.breast.2022.02.011. （IF:4.254） 

32. Ma Z, Zhang Y, Zhu M, Feng L,Zhang Y*,An Z*. Interstitial lung disease associated with anti-HER2 anti-bodydrugconjugates: results from clinical trials and the WHO'spharmacovigilancedatabase. Expert Rev Clin Pharmacol. 2022Nov;15(11):1351-1361. doi:10.1080/17512433.2022.2121705.    （IF:4.108） 

33. Hu T#*, Ren L#, Li H, An Z*.Effects of Vitamin D supplementation ordeficiency on metabolic phenotypes inmice of different sexes. J Steroid BiochemMol Biol. 2023 May;229:106250. doi:10.1016/j.jsbmb.2023.106250.   （IF:4.1）     

34. Wang X#, Zhang Y#, Huang C,Yang H,Jiang C, Yu X, Zhao R, Hong J, Zhang Y, Wang Y, Zhao R, An Z*,Tong Z*. Boostervaccines dose reduced mortality in hospitalized COVID-19patients requiringoxygen supplementation: Evidence from the Beijing Omicronoutbreak. Hum VaccinImmunother. 2024 Dec 31;20(1):2361500. doi:10.1080/21645515.2024.2361500. Epub2024 Jun 21.       （IF:4.1）     

35. Xuan L, Ren L, Zhang W, An Z.Identification of Novel Biomarkers Associated with Corticosteroid Resistance inAsthma by Bioinformatics Analysis and Experimental Validation. J Inflamm Res.2025 Sep 9;18:12379-12400. doi: 10.2147/JIR.S527640. PMID: 40951447 ; PMCID:PMC12433222I.  （IF:4.1）     

36. An Z#, Wang X#, Li P#, He J, Liu L*.Exploring the metaboliccharacteristics and pharmacokinetic variation ofparoxetine in healthyvolunteers using a pharmacometabonomic approach. J PharmBiomed Anal. 2021 Sep10;204:114224. doi: 10.1016/j.jpba.2021.114224.    （IF:3.935） 

37. Zhou H#, Sun X#, Lyu S, Yu X,Li R, WangH*, An Z*. Evaluation of Tigecycline Utilization and Trendsin AntibacterialResistance from 2018 to 2021 in a Comprehensive TeachingHospital in China.Infect Drug Resist. 2023 Feb 14;16:879-889. doi:10.2147/IDR.S395158.       （IF:3.9）

38. Zhang J, Han L, Liu H, ZhangH*, An Z*.Metabolomic analysis reveals the metabolic disturbance inaortic dissection:Subtype difference and accurate diagnosis. Nutr MetabCardiovasc Dis. 2023Aug;33(8):1556-1564. doi: 10.1016/j.numecd.2023.05.006.       （IF:3.9）     

39. Liu H#, Zhao Z#, Wang Y, Liu L,Yang Y,An Z*. Study on the Relationship between Rivaroxaban and FactorXa Activity inBlood Based on HPLC-MS/MS. Curr Drug Metab.2021;22(14):1132-1138. doi:10.2174/1389200222666211126093627.      （IF:3.731） 

40. Tang B#, Zhang Y#, Wang Y, WangX, AnZ*, Yu X*. Effect of bariatric surgery on long-term cardiovascularoutcomes: asystematic review and meta-analysis of population-based cohortstudies. SurgObes Relat Dis. 2022 May 16:S1550-7289(22)00202-7. doi:10.1016/j.soard.2022.05.007.       （IF:3.709） 

41. Xu M, Ma Z, Feng X, An Z*.Comparison offour criteria for potentially inappropriate medications in olderpatients withnewly diagnosed non-small cell lung cancer. Expert Opin Drug Saf.2024 May22:1-7. doi: 10.1080/14740338.2024.2348567.  （IF:3.6）     

42. Wang X, Luo L, Wang Y, An Z*.Effect ofPlatelet Function Testing Guidance on Clinical Outcomes for PatientswithIntracranial Aneurysms Undergoing Endovascular Treatment. AJNR Am JNeuroradiol.2023 Aug;44(8):928-933. doi: 10.3174/ajnr.A7923.        （IF:3.5）     

43. Sun Y, Cong L, Yang S, Zhao R, AnZ*,Liu L*. Moxifloxacin Induced Liver Injury by Causing LachnospiraceaeDeficiencyand Interfering with Butyric Acid Production through Gut-Liver Axis.DisMarkers. 2022 Apr 29;2022:9302733. doi: 10.1155/2022/9302733. （IF:3.464） 

44. Hu T#, An Z#, Li H, LiuY, Xia L, Qiu L,Yao A, Ma L*, Liu L*. UHPLC-MS/MS-Based Metabolomics andClinical PhenotypesAnalysis Reveal Broad-Scale Perturbations in EarlyPregnancy Related toGestational Diabetes Mellitus. Dis Markers. 2022 Aug24;2022:4231031. doi:10.1155/2022/4231031.   （IF:3.464） 

45. Yang H, Zhang Y, Wang Z, Xu M,Wang Y,Zhang Y, Feng X, An Z*. Adherence and recommended optimaltreatment to Azvudineapplication for the treatment of outpatient COVID-19patients: A real-worldretrospective study. Heliyon. 2024 May 4;10(9):e30619.doi: 10.1016/j.heliyon.2024.e30619.       （IF:3.4）     

46. Zhu Y, Zhang Y, Yang H, Jiang C, ChenW, Zhang H, Zhang X, Wu H, Li J, An Z. Prevalence of potentially inappropriateuse of antiviral therapy with simnotrelvir-ritonavir versusnirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing,China. BMJ Open Respir Res. 2025 Dec 4;12(1):e003043. doi:10.1136/bmjresp-2024-003043.  （IF:3.4）   

47. Hu T, Shi C, Liu L, Li P, SunY, An Z*.A single-injection targeted metabolomics profiling method fordetermination ofbiomarkers to reflect tripterygium glycosides efficacy andtoxicity. ToxicolAppl Pharmacol. 2020 Jan 15;389:114880. doi:10.1016/j.taap.2020.114880.    （IF:3.347）

48. An Z, Hu T, Lv Y, Li P, Liu L*.Targeted amino acid and related aminesanalysis based on iTRAQ®-LC-MS/MS fordiscovering potential hepatotoxicitybiomarkers. J Pharm Biomed Anal. 2020 Jan30;178:112812. doi:10.1016/j.jpba.2019.112812. （IF:3.209） 

49. Yang H, Zhang Y, Feng X*, An Z*.Bleeding Complications in Vancomycin-Induced Thrombocytopenia: A Real-worldPostmarketing Pharmacovigilance Analysis. Clin Ther. 2023 Sep;45(9):868-872.doi: 10.1016/j.clinthera.2023.06.022.   （IF:3.2）

50.  YangH, Wang Z, Wang C, Zhang Y, Han S, An Z*. Cost-effectiveness of Azvudine forHigh-risk Outpatients with Mild-to-moderate Coronavirus Disease 2019 in China.Clin Ther. 2024 Sep;46(9):e1-e5. doi: 10.1016/j.clinthera.2024.07.009.   （IF:3.2）

51.  YuX, Zhang Y, An Z, Feng X, Yang H. Thrombotic Microangiopathy Associated withCalcineurin Inhibitors: A Real-World Analysis of Postmarketing SurveillanceData. Clin Ther. 2025 Feb;47(2):117-122. doi: 10.1016/j.clinthera.2024.11.017. （IF:3.2）

52.  Liu D#, An Z#, Li P,Chen Y, Zhang R, Liu L*,He J*, Abliz Z. A targeted neurotransmitterquantification and nontargetedmetabolic profiling method forpharmacometabolomics analysis of olanzapine byusing UPLC-HRMS. RSC Adv. 2020May 13;10(31):18305-18314. doi:10.1039/d0ra02406f.     （IF:3.119） 

53. Ma Z, Pei J, Zhang Y, Li H, SunD, ZhangY*, An Z*. Interstitial pneumonitis associated with EGFR/ ALKtyrosine kinaseinhibitors used in non-small cell lung cancer: anobservational, retrospective,pharmacovigilance study. Expert Opin Drug Saf.2023 Mar;22(3):237-242. doi:10.1080/14740338.2022.2110235.        （IF:3.1）

54. Jian Y, Han F, Zhu Y, Geng C,Zhang Y,Wu Y, Leng Y, Chen W, An Z*, Zhu H*. Paired comparisons ofvenetoclaxconcentration in cerebrospinal fluid, bone marrow, and plasma inacute leukemiapatients. Clin Transl Sci. 2024 Sep;17(9):e70006. doi:10.1111/cts.70006.     （IF:3.1）

55. Zhang Y, Ma K, Hou W, Liu X,Chen J,Wang Y, Zhu Y, Qian Q, An Z*, Yang H*. Inappropriate prescribingofNirmatrelvir/Ritonavir in Solid Organ Transplantation with COVID-19Infection: AMulticenter Retrospective Study. Clin Transl Sci.  （IF:3.1）

56. Li B, Yang S, Ye J, Chu S, ChenN*, AnZ*. Flavin-containing monooxygenase 1 deficiency promotesneuroinflammation indopaminergic neurons in mice. Neurosci Lett. 2021 Nov1;764:136222. doi:10.1016/j.neulet.2021.136222.      （IF:3.046）

57. Yang H, Ding Z, An Z*. Urinarytractinfection following the use of BTK inhibitors: a real-world analysisofpost-marketing surveillance data. Expert Opin Drug Saf. 2024Mar;23(3):333-338.doi: 10.1080/14740338.2023.2251376.  （IF:3） 

58. Yang J, Yang H, An Z*.Catatonia relatedto tacrolimus: a real world pharmacovigilance study of FDAadverse eventreporting system (FAERS) database. Expert Opin Drug Saf.Published online August21, 2024. doi:10.1080/14740338.2024.2393757  （IF:3）

59. Zhang Y#, Ma Z#, Sun X, ZhangY, Zhu M,Zhang S, Feng X, An Z*. Anticancer drug-induced interstitiallung disease: acritical appraisal of clinical practice guidelines andconsensus statements.Expert Opin Drug Saf. 2024 Feb 20:1-9. doi:10.1080/14740338.2024.2315113.   （IF:3） 

60. Wang X, Yang H, An Z*.Tacrolimusrelated diabetic ketoacidosis and hyperglycaemic hyperosmolarnonketoticsyndrome: an observational, retrospective, pharmacovigilance study.Expert OpinDrug Saf. 2024 Aug 19:1-6. doi: 10.1080/14740338.2024.2393278.        （IF:3）

61. Zhu Y, Yang H, An Z*. Skin cancerassociated with calcineurin inhibitors treatment: analysis of FAERS database.Expert Opin Drug Saf. 2024 Dec 25:1-7. doi: 10.1080/14740338.2024.2443783.       （IF:3）

62. Ma Z, Zhang Y, Sun D, Zhu M, Yi J,Zhang Y, An Z, Zhang Y. Thromboembolic and bleeding events associated withangiogenesis inhibitors in cancer patients. Expert Opin Drug Saf. 2025 May21:1-10. doi: 10.1080/14740338.2025.2494688. （IF:3）

63. Zhang Y#, Wang X#, Huang C,Yang H,Jiang C, Yu X, Hong J, Zhang Y, Wang Y, Zhao R, An Z*, TongZ*.Nirmatrelvir-Ritonavir Reduced Mortality in Hospitalized Patients withCOVID-19During the Omicron Outbreak: Real-World Evidence from Beijing. InfectDrugResist. 2024 Apr 8;17:1367-1377. doi: 10.2147/IDR.S445826.       （IF:2.9）     

64. Wei R, Li K, Wang H, Cai X, Liu N, AnZ, Zhou H. Using Machine Learning to Predict Linezolid-AssociatedThrombocytopenia. Infect Drug Resist. 2025 May 23;18:2653-2661. doi:10.2147/IDR.S479658.    （IF:2.9）

65. Ding X, Zhou J, Wang Z, Bo Y, Abliz Z,An Z, Yang F, Chen Y. Lipidomic machine learning predictor for progression ofgastric cancer. Clin Chim Acta. 2026 Jan 30;580:120731. doi:10.1016/j.cca.2025.120731.   （IF:2.9）

66. Li B, Liu M, Wang Y, Zhang H,Xuan L,Huang K, An Z*. Association of Severe Vitamin D Deficiency withHospitalizationin the Previous Year in Hospitalized Exacerbated COPD Patients.Int J ChronObstruct Pulmon Dis. 2024 Jun 25;19:1471-1478. doi:10.2147/COPD.S461029.   （IF:2.7）

67. Hu T,Han F, An Z*.Comprehensiveprofiling of serum glycosphingolipids to discover the diagnostic biomarkers oflung cancer and uncover the variation of glycosphingolipids network indifferent lung cancer subtypes. Anal Methods.（IF:2.7）

68. An Z*, Sun Y, Shi C, Liu L*. Metabonomic and transcriptomic analysesofTripterygium glycosides tablet-induced hepatotoxicity in rats. DrugChemToxicol. 2022 May 23:1-15. doi: 10.1080/01480545.2022.2077360. （IF:2.597） 

69. Hu T#*, Li H#, Liu H, Cong L,Liu L, AnZ*. High throughput UHPLC-MS/MS method for the simultaneousquantification ofsix vitamin D metabolites: application for vitamin Ddetermination in patientsafter liver or kidney transplantation. Anal Methods.2020 Dec7;12(46):5591-5600. doi: 10.1039/d0ay01088j.   （IF:2.596）

70. An Z*, Shi C, Li P, Liu L*. Stabilityof amino acids and related aminesin human serum under different preprocessingand pre-storage conditions basedon iTRAQ®-LC-MS/MS. Biol Open. 2021 Feb26;10(2):bio055020. doi:10.1242/bio.055020.     （IF:2.422）

71. An Z*, Sun Y, Shi C, Liu L*.Metabonomic and transcriptomic analyses of Tripterygium glycosidestablet-induced hepatotoxicity in rats. Drug Chem Toxicol. 2022 May 23:1-15.doi: 10.1080/01480545.2022.2077360.     （IF:2.4）

72. Wang X, Tang B, Liu Y, Wang X,Wang S,An Z*, Wang H*. Clinical practice guidelines for management ofdual antiplatelettherapy in patients with noncardiac surgery: A criticalappraisal using theAGREE II instrument. J Clin Pharm Ther. 2022May;47(5):652-661. doi:10.1111/jcpt.13593.   （IF:2.145） 

73. Wang X, Liu Y, Zhang Y, Ma Z, An Z.Implementation of Guideline-Based Use of Proton Pump Inhibitors forPerioperative Stress Ulcer Prophylaxis: A Pre-Post Study Guided by CFIR-ERIC.Patient Prefer Adherence. 2025 Mar 18;19:635-645. doi: 10.2147/PPA.S496310   (IF:2.0)

74. Liu H, Yu X, Hu T, Han F, AnZ*, ZhaoR*. Simultaneous determination of four antibiotics in human plasmabyhigh-performance LC-MS/MS: application to therapeutic drugmonitoring.Bioanalysis. 2023 Mar;15(5):269-282. doi: 10.4155/bio-2023-0020. （IF:1.8）

75. Han F, Liu H, Hu T, Li P, ZhaoR, AnZ*.Development and validation of a rapid HPLC-MS/MS method forsimultaneousdetermination of cyclosporine A and tacrolimus in whole blood forroutinetherapeutic drug monitoring in organ transplantation.Rapid Commun MassSpectrom.   （IF:1.8）